Medication info
Flogaduo Extended Release Tablet 10/1000 milligrams

Flogaduo Extended Release Tablet 10/1000 milligrams

Prescription medicationTabletOral
Ingredient · strength
Dapagliflozin citric acid›14.7mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
NexPharm Korea Co., Ltd.
Appearance
Yellow, oval, film-coated tablet with a biconvex shape
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202107220 · Approved 2021.10.29 · Insurance code 662504680

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dosage of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as two 5mg/1000mg tablets. When used as initial therapy in patients with no prior experience with antidiabetic drug therapy, the recommended starting dose of this medicine is one 5mg/500mg or 10mg/500mg tablet once daily. The dose should be titrated gradually to reduce the gastrointestinal adverse effects of metformin. For patients being treated with metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this medicine should provide the patient's current dose of metformin or the nearest appropriate therapeutic dose. For patients switching from combination therapy with dapagliflozin and metformin to this medicine, the dose of this medicine may be started at the doses of dapagliflozin and metformin previously being taken. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. No dosage adjustment is required for patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or more and less than 60 mL/min/1.73 m2 who do not have other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medicine is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months. Since metformin is excreted through the kidneys and renal function is more likely to decline in older adults, this medicine should be used with caution as age increases.

Ingredients

Manufacturer
NexPharm Korea Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes
  • poor blood glucose control
  • cardiovascular diseases
  • cardiovascular risk factors
View approved original text

This medication helps control blood sugar levels in adults with type 2 diabetes by using dapagliflozin and metformin together. It is administered to patients who are also following dietary and exercise regimens, and is particularly effective when blood sugar is not sufficiently controlled. It can also be applied to diabetes patients with cardiovascular diseases or risk factors. However, it is important to refer to professional information for detailed information regarding the occurrence of cardiovascular events. This medication aids diabetes management by improving blood glucose control.

How to take

Adult dose

The dosage of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as two 5mg/1000mg tablets. When used as initial therapy in patients with no prior experience with antidiabetic drug therapy, the recommended starting dose of this medicine is one 5mg/500mg or 10mg/500mg tablet once daily. The dose should be titrated gradually to reduce the gastrointestinal adverse effects of metformin. For patients being treated with metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this medicine should provide the patient's current dose of metformin or the nearest appropriate therapeutic dose. For patients switching from combination therapy with dapagliflozin and metformin to this medicine, the dose of this medicine may be started at the doses of dapagliflozin and metformin previously being taken. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. No dosage adjustment is required for patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or more and less than 60 mL/min/1.73 m2 who do not have other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medicine is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months. Since metformin is excreted through the kidneys and renal function is more likely to decline in older adults, this medicine should be used with caution as age increases.

Precautions

This medication is an anti-diabetic drug that helps control blood sugar levels and contains two components that work to lower blood sugar. While taking this medication, rare but serious metabolic complications known as lactic acidosis can occur, particularly in patients with poor kidney function or issues involving heart and liver function. Additionally, the risk of hypoglycemia may increase when used in conjunction with insulin or sulfonylureas, so close monitoring of blood sugar changes is necessary. This medication should not be administered to patients with moderate to severe kidney impairment, dehydration, acute infections, severe heart failure, or acute myocardial infarction. Patients scheduled for surgery or radiological contrast examinations should temporarily discontinue this medication and resume after confirming normal kidney function post-examination. Pregnant or breastfeeding women should not take this medication, and special caution is needed for children or elderly individuals aged 80 and over. This medication can cause a decrease in fluid volume or low blood pressure, so elderly patients or those on diuretics should frequently check their blood pressure and fluid status. During treatment, incidences of genital and urinary tract infections may increase, and immediate medical attention is necessary if symptoms of infection arise. Vitamin B12 levels may decrease, so regular testing of vitamin B12 levels is advisable during long-term use. Alcohol consumption can increase the risk of lactic acidosis, so it is safer to avoid drinking during treatment. Patients should be aware of symptoms related to hypoglycemia, lactic acidosis, and ketoacidosis while on this medication, and consult with medical professionals if any abnormal symptoms appear. Finally, this medication should not be used in children, pregnant women, or patients with severe kidney impairment, and because there are drug interactions, it is essential to inform healthcare providers about any other medications being taken.

Side effects

  • Severe lactic acidosis
  • severe hypoglycemia
  • vulvitis
  • balanitis
  • genital infections
  • urinary tract infections
  • fungal infections
  • hypoglycemia
  • decreased fluid volume
  • thirst
Show 84 more
  • diabetic ketoacidosis
  • dizziness
  • constipation
  • dry mouth
  • back pain
  • dysuria
  • polyuria
  • nocturia
  • vulvar itching
  • genital itching
  • elevated hematocrit
  • decreased renal creatinine clearance
  • dyslipidemia
  • elevated serum creatinine
  • elevated blood urea
  • weight loss
  • ketoacidosis
  • urosepsis
  • pyelonephritis
  • acute kidney injury
  • renal dysfunction
  • rash
  • diarrhea
  • nausea
  • vomiting
  • decreased vitamin B12
  • Guillain-Barré syndrome
  • bacterial pneumonia
  • sialadenitis
  • chest pain
  • thermal burn
  • wrist fracture
  • gastrointestinal stromal tumor
  • malignant neoplasm of the lung
  • uterine fibroids
  • atrial fibrillation
  • acute cholecystitis
  • upper abdominal pain
  • indigestion
  • abdominal discomfort
  • abdominal pain
  • gastric ulcer
  • irritable bowel syndrome
  • salivary gland mass
  • toothache
  • headache
  • facial paralysis
  • peripheral neuropathy
  • sensory disturbance
  • drowsiness
  • tremor
  • nasopharyngitis
  • pharyngitis
  • adenovirus conjunctivitis
  • shingles
  • pneumonia
  • rhinitis
  • increased alanine aminotransferase
  • increased blood sugar
  • tendonitis
  • arthralgia
  • myalgia
  • myofascial pain syndrome
  • osteoarthritis
  • osteochondrosis
  • limb pain
  • pericapsulitis
  • tenosynovitis
  • trigger finger
  • myasthenia
  • fatigue
  • peripheral edema
  • edema
  • pain
  • vitamin D deficiency
  • hyperglycemia
  • urethral syndrome
  • cough
  • hyperventilation
  • itching
  • palpitations
  • insomnia
  • type 2a hyperlipidemia
  • audiogenic hearing loss

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to protect it from exposure to air and moisture. It is important to maintain a storage temperature between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

Yellow, oval, film-coated tablet with a biconvex shape

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.